Thomas Waldmann
0000-0003-4500-6660
National Cancer Institute
6 papers found
Refreshing results…
A very long-acting IL-15: implications for the immunotherapy of cancer
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma
Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges
Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas
Missing publications? Search for publications with a matching author name.